Watchlist Price Alert

Dr. Reddy's Laboratories ... (RDY)

NYSE: RDY · Real-Time Price · USD

14.44

0.05 (0.35%)

At close: May 16, 2025, 3:59 PM

14.31

-0.90%

After-hours: May 16, 2025, 05:39 PM EDT

0.35% (1D)

Bid	14.3
Market Cap	12.03B
Revenue (ttm)	311.31B
Net Income (ttm)	53.68B
EPS (ttm)	0.8
PE Ratio (ttm)	18.05
Forward PE	0.21
Analyst	Buy

Ask	15
Volume	919,784
Avg. Volume (20D)	2,162,738
Open	14.29
Previous Close	14.39
Day's Range	14.28 - 14.46
52-Week Range	12.26 - 16.89
Beta	0.34

About RDY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RDY

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RDY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Dr. Reddy's Laboratories has released their quartely earnings on May 9, 2025:

Revenue of $996M exceeds estimates by $129.49M, with 20.14% YoY growth.

EPS of 0.22 exceeds estimates by 0.02, with 22.22% YoY growth.

Why Price Moved

5 days ago

+3.96%

Dr. Reddy's Laboratories shares are trading hgher ... Unlock content with Pro Subscription

3 months ago

-6.23%

Dr. Reddy's Laboratories shares are trading lower. The company reported Q3 financial results.

News

3 days ago · seekingalpha.com

Dr. Reddy's Continues To Be A Good Buy At Current Valuation

I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY r...

5 days ago · zacks.com

RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

5 days ago · youtube.com

Generics won't be affected by Trump's pricing policy, says Dr. Reddy's

Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans ...

1 week ago · seekingalpha.com

Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Richa Periwal - Head, IR and Analytics Erez Israeli - CEO M V Narasimham - CF...

1 week ago · businesswire.com

Dr. Reddy's Q4 & Full Year FY25 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.

1 month ago · zacks.com

RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.

2 months ago · zacks.com

FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review

Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.

2 months ago · businesswire.com

Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #AVT03--Alvotech and Dr. Reddy's announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and...

2 months ago · businesswire.com

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.